1.
Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry
2.
3.
Sex differences in characteristics and outcome in acute coronary syndrome patients in the Netherlands